Does the media prefer CRSP or AKTS?

In the previous week, CRISPR Therapeutics had 8 more articles in the media than Aktis Oncology. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 5 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 1.59 beat CRISPR Therapeutics' score of 0.36 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Aktis Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, GRFS or AKTS?

Grifols has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $7.42B 0.72 $454.82M $0.19 41.47 Aktis Oncology $6.50M 220.38 -$63.73M -$0.82 N/A

Does the media refer more to AKTS or ACAD?

In the previous week, ACADIA Pharmaceuticals had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 9 mentions for ACADIA Pharmaceuticals and 5 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 1.59 beat ACADIA Pharmaceuticals' score of 1.56 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ACADIA Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is EWTX or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Aktis Oncology N/A N/A N/A

Does the media favor EWTX or AKTS?

In the previous week, Edgewise Therapeutics had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 9 mentions for Edgewise Therapeutics and 5 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 1.59 beat Edgewise Therapeutics' score of 1.20 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is DYN or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Aktis Oncology N/A N/A N/A

Does the media refer more to DYN or AKTS?

In the previous week, Dyne Therapeutics had 5 more articles in the media than Aktis Oncology. MarketBeat recorded 10 mentions for Dyne Therapeutics and 5 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 1.59 beat Dyne Therapeutics' score of 1.46 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Aktis Oncology (AKTS) Competitors

$26.65 -0.27 (-1.00%)

As of 09/3/2026 04:00 PM Eastern

Compare

AKTS vs. CRSP, GRFS, ACAD, EWTX, and DYN

Should you buy Aktis Oncology stock or one of its competitors? Aktis Oncology's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Grifols (GRFS), ACADIA Pharmaceuticals (ACAD), Edgewise Therapeutics (EWTX), and Dyne Therapeutics (DYN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aktis Oncology compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Aktis Oncology (NASDAQ:AKTS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aktis Oncology has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. Aktis Oncology's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Aktis Oncology	N/A	N/A	N/A

Aktis Oncology has higher revenue and earnings than CRISPR Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,556.13	-$581.60M	-$4.76	N/A
Aktis Oncology	$6.50M	220.38	-$63.73M	-$0.82	N/A

In the previous week, CRISPR Therapeutics had 8 more articles in the media than Aktis Oncology. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 5 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 1.59 beat CRISPR Therapeutics' score of 0.36 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Aktis Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CRISPR Therapeutics presently has a consensus price target of $68.06, suggesting a potential upside of 20.47%. Aktis Oncology has a consensus price target of $35.00, suggesting a potential upside of 31.33%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Aktis Oncology is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Aktis Oncology beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aktis Oncology compare to Grifols?

Grifols (NASDAQ:GRFS) and Aktis Oncology (NASDAQ:AKTS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Grifols has a net margin of 5.54% compared to Aktis Oncology's net margin of 0.00%. Grifols' return on equity of 6.21% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Aktis Oncology	N/A	N/A	N/A

Grifols has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$7.42B	0.72	$454.82M	$0.19	41.47
Aktis Oncology	$6.50M	220.38	-$63.73M	-$0.82	N/A

28.8% of Aktis Oncology shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 3.3% of Aktis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Grifols presently has a consensus target price of $10.00, indicating a potential upside of 26.90%. Aktis Oncology has a consensus target price of $35.00, indicating a potential upside of 31.33%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Aktis Oncology had 5 more articles in the media than Grifols. MarketBeat recorded 5 mentions for Aktis Oncology and 0 mentions for Grifols. Aktis Oncology's average media sentiment score of 1.59 beat Grifols' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Grifols	Neutral
Aktis Oncology	Very Positive

Summary

Aktis Oncology beats Grifols on 9 of the 16 factors compared between the two stocks.

How does Aktis Oncology compare to ACADIA Pharmaceuticals?

Aktis Oncology (NASDAQ:AKTS) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

ACADIA Pharmaceuticals has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	220.38	-$63.73M	-$0.82	N/A
ACADIA Pharmaceuticals	$1.07B	4.48	$391M	$2.22	12.55

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Aktis Oncology's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Aktis Oncology presently has a consensus target price of $35.00, suggesting a potential upside of 31.33%. ACADIA Pharmaceuticals has a consensus target price of $34.36, suggesting a potential upside of 23.33%. Given Aktis Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Aktis Oncology is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, ACADIA Pharmaceuticals had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 9 mentions for ACADIA Pharmaceuticals and 5 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 1.59 beat ACADIA Pharmaceuticals' score of 1.56 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ACADIA Pharmaceuticals	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

ACADIA Pharmaceuticals beats Aktis Oncology on 11 of the 16 factors compared between the two stocks.

How does Aktis Oncology compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Aktis Oncology (NASDAQ:AKTS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Edgewise Therapeutics currently has a consensus price target of $50.33, indicating a potential upside of 19.98%. Aktis Oncology has a consensus price target of $35.00, indicating a potential upside of 31.33%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Aktis Oncology's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Aktis Oncology	N/A	N/A	N/A

Aktis Oncology has higher revenue and earnings than Edgewise Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Aktis Oncology	$6.50M	220.38	-$63.73M	-$0.82	N/A

28.8% of Aktis Oncology shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Edgewise Therapeutics had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 9 mentions for Edgewise Therapeutics and 5 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 1.59 beat Edgewise Therapeutics' score of 1.20 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Aktis Oncology beats Edgewise Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Aktis Oncology compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Aktis Oncology (NASDAQ:AKTS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Aktis Oncology's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Aktis Oncology	N/A	N/A	N/A

In the previous week, Dyne Therapeutics had 5 more articles in the media than Aktis Oncology. MarketBeat recorded 10 mentions for Dyne Therapeutics and 5 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 1.59 beat Dyne Therapeutics' score of 1.46 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aktis Oncology has higher revenue and earnings than Dyne Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Aktis Oncology	$6.50M	220.38	-$63.73M	-$0.82	N/A

Dyne Therapeutics presently has a consensus target price of $34.42, indicating a potential upside of 37.94%. Aktis Oncology has a consensus target price of $35.00, indicating a potential upside of 31.33%. Given Dyne Therapeutics' higher probable upside, equities analysts plainly believe Dyne Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Dyne Therapeutics and Aktis Oncology tied by winning 7 of the 14 factors compared between the two stocks.

Get Aktis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTS vs. The Competition

Export

Metric	Aktis Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.45B	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-32.50	12.66	273.28	25.38
Price / Sales	220.38	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	2.95	16.29	12.89	6.14
Net Income	-$63.73M	-$22.72M	$3.47B	$349.01M
7 Day Performance	3.37%	0.34%	0.61%	-0.27%
1 Month Performance	16.68%	8.52%	5.73%	0.68%
1 Year Performance	N/A	52.66%	25.37%	14.84%

Aktis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTS Aktis Oncology	2.9862 of 5 stars	$26.65 -1.0%	$35.00 +31.3%	N/A	$1.45B	$6.50M	N/A	76
CRSP CRISPR Therapeutics	2.4106 of 5 stars	$57.08 -4.1%	$68.06 +19.2%	+6.6%	$5.52B	$3.51M	N/A	460	News Coverage Analyst Forecast
GRFS Grifols	4.2844 of 5 stars	$7.99 -0.1%	$10.00 +25.2%	-17.8%	$5.44B	$8.51B	42.05	25,247
ACAD ACADIA Pharmaceuticals	4.8259 of 5 stars	$29.65 +0.5%	$34.19 +15.3%	+8.3%	$5.11B	$1.07B	13.36	510	Positive News
EWTX Edgewise Therapeutics	3.408 of 5 stars	$44.72 +1.2%	$50.33 +12.6%	+186.5%	$4.86B	N/A	N/A	60	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aktis Oncology (AKTS) Competitors

AKTS vs. CRSP, GRFS, ACAD, EWTX, and DYN

How does Aktis Oncology compare to CRISPR Therapeutics?

Summary

How does Aktis Oncology compare to Grifols?

Summary

How does Aktis Oncology compare to ACADIA Pharmaceuticals?

Summary

How does Aktis Oncology compare to Edgewise Therapeutics?

Summary

How does Aktis Oncology compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aktis Oncology (AKTS) Competitors

AKTS vs. CRSP, GRFS, ACAD, EWTX, and DYN

How does Aktis Oncology compare to CRISPR Therapeutics?

Do institutionals and insiders hold more shares of CRSP or AKTS?

Is CRSP or AKTS more profitable?

Which has stronger earnings & valuation, CRSP or AKTS?

Does the media prefer CRSP or AKTS?

Do analysts recommend CRSP or AKTS?

Summary

How does Aktis Oncology compare to Grifols?

Is GRFS or AKTS more profitable?

Which has preferable earnings and valuation, GRFS or AKTS?

Do institutionals & insiders believe in GRFS or AKTS?

Do analysts recommend GRFS or AKTS?

Does the media favor GRFS or AKTS?

Summary

How does Aktis Oncology compare to ACADIA Pharmaceuticals?

Which has higher valuation and earnings, AKTS or ACAD?

Is AKTS or ACAD more profitable?

Do analysts recommend AKTS or ACAD?

Do institutionals and insiders hold more shares of AKTS or ACAD?

Does the media refer more to AKTS or ACAD?

Summary

How does Aktis Oncology compare to Edgewise Therapeutics?

Do analysts rate EWTX or AKTS?

Is EWTX or AKTS more profitable?

Which has better valuation & earnings, EWTX or AKTS?

Do institutionals & insiders have more ownership in EWTX or AKTS?

Does the media favor EWTX or AKTS?

Summary

How does Aktis Oncology compare to Dyne Therapeutics?

Is DYN or AKTS more profitable?

Does the media refer more to DYN or AKTS?

Which has preferable valuation and earnings, DYN or AKTS?

Do analysts prefer DYN or AKTS?

Do institutionals and insiders believe in DYN or AKTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools